Newsroom

Citeline in the News

FEATURED IN

All coverage

Media mentions

Dec. 22, 2025 – An article in WIRED on approval of an oral version of Novo Nordisk’s Wegovy featured obesity market insights from Citeline analyst Tim Blackstock
Dec. 15, 2025 – An article from PharmaVoice on the Biosecure Act cited a statistic from Citeline’s Clinical Trials Roundup
Dec. 8, 2025 – In a video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed how sponsors and CROs are adapting to evolving ICH GCP guidelines to ensure patient protection and preserve data integrity while maintaining innovation
Dec. 8, 2025 – Applied Clinical Trials’ Dec. 5 ACT Brief podcast featured insights from Heidi Chen, Associate Director of Research & Commercial Services at Citeline, on the continued surge in CNS and autoimmune trials based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
Dec. 8, 2025 – Applied Clinical Trials’ Dec. 8 ACT Brief podcast featured insights from Heidi Chen, Associate Director of Research & Commercial Services at Citeline, on how sponsors and CROs are maintaining innovation as they adapt to evolving ICH GCP guidelines
Dec. 4, 2025 – Applied Clinical Trials’ Dec. 4 ACT Brief podcast featured insights from Heidi Chen, Associate Director of Research & Commercial Services at Citeline, on the shift toward more targeted and strategy-driven clinical development based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
Dec. 4, 2025 – In a video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed the shift toward more targeted and strategy-driven clinical development based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
Dec. 4, 2025 – In a video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed growth in CNS and autoimmune trials based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
Nov. 12, 2025 – In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed the trends of sponsors assuming a larger role in site selection and CRO oversight and using robust data that includes real-world data to validate feasibility before launch
Nov. 12, 2025 – In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed converting identified patients into enrolled participants through organizing data assets, activating non-research HCPs, and building avenues for referral with compliant recompense
Nov. 12, 2025 – Applied Clinical Trials’ Nov. 12 ACT Brief podcast featured insights from Matt Holms, Vice President of Sales at Citeline, on the growing trend of sponsors assuming greater data-backed oversight of site selection and CRO management
Nov. 10, 2025 – In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed the need to tailor patient recruitment strategies by indication and geography and to adopt data-driven matching with supported referrals over site expansion and generic advertising
Nov. 7, 2025 – Applied Clinical Trials’ ACT Brief podcast featured insights from Matt Holms, Vice President of Sales at Citeline, on the bottlenecks that continue to stall recruitment and initiatives that can help break through the logjam
Nov. 6, 2025 – In a PharmaVoice article, Heidi Chen, Associate Director of Research and Commercial Services at Citeline and co-author of its annual Clinical Trials Roundup, discussed the accelerating research boom in China as well as other trends outlined in the report
Nov. 6, 2025 – In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed how technology and data-driven strategies can help overcome the persistent barriers slowing patient recruitment
Oct. 31, 2025 – A PharmaVoice article on the launch of a pivotal trial for MediciNova’s disease-modifying ALS drug MN-166 cited a statistic from Citeline’s Clinical Trials Roundup
Oct. 23, 2025 – In an Endpoints article on the potential of neurology assets in M&As, Citeline analyst Emma Wille commented on how the adoption of AI might speed identification of successful candidates (subscription required)
Oct. 24, 2025 – In a Fierce Pharma article, senior analyst David Dahan weighs in on the comeback of GSK’s Blenrep
Oct. 1, 2025 – In a PharmaVoice article, senior analyst Natasha Boliter discusses the opportunities and roadblocks around at-home vaccines
Sept. 25, 2025 – In a Daily Mail article, David Wallace, Executive Editor of Generics Bulletin, sheds light on anticipated generic versions of weight-loss drugs (subscription required)
Aug. 22, 2025 – A PharmaVoice article about recent large pharma breakups with biotechs cites data from the Pharma R&D Review
July 29, 2025 – In an article in Precision Medicine Online about AstraZeneca’s Tagrisso’s Q2 success, Citeline analyst Neha Anand shares insights into growing competition in the ADC therapy market (subscription required)
July 29, 2025 – In Part 5 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses what Emrelis could mean for AbbVie’s long-term positioning in solid tumor treatment markets
July 24, 2025 – In Part 4 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses what AbbVie’s Emrelis approval means for pharma and biotech ADC strategies
July 23, 2025 – In Part 3 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses how Emrelis is expanding treatment options for solid tumors with C-MET overexpression
July 22, 2025 – In Part 2 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses how approval of AbbVie’s antibody-drug conjugate (ADC) Emrelis signals the FDA’s posture toward ADCs in oncology
July 21, 2025 – In an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses AbbVie’s newly approved antibody-drug conjugate (ADC) Emrelis
July 18, 2025 – The New York Times cited Citeline data in an article on the impact proposed cuts to medical research and health agencies could have on drug development (subscription required)
July 1, 2025 – A Forbes feature article includes Citeline data and insights from Daniel Chancellor, VP of Thought Leadership at Citeline’s parent company, Norstella
June 27, 2025 – Marketplace quotes Mark Landsell and Citeline data in an article on innovative drug development in China
June 16, 2025 – In a BioXconomy article, deals analyst Jenny Tan sounds off on the BioNTech acquisition of CureVac
June 16, 2025 – A Reuters article on US drugmakers turning to Chinese companies as they face patent expirations includes data from Citeline’s Pharma R&D Review
June 15, 2025 – A MedCity News article recapping ASCO 2025 features commentary from Citeline analyst Anna Simmons on breast cancer treatments
May 30, 2025 – In a PharmaVoice article on the FDA’s approval of AbbVie’s ADC Emrelis, Citeline analyst Neha Anand offers commentary on the ADC market and challenges
May 29, 2025 – In a commentary piece in Molecular Therapy, “The landscape of cell and gene therapy today,” ASGCT’s David Barrett and Citeline’s Daniel Digaudio focus on advances in CGT (subscription required)
May 15, 2025 – MedCity News has included analyst Neha Anand’s commentary on FDA approval of AbbVie’s ADC for lung cancer
May 13, 2025 – UK national publication The i Paper featured commentary from Tim Blackstock on the potential uses of GLP-1s beyond obesity and diabetes
April 25, 2025 – On the Pharmaceutical Commerce podcast, VP of Clinical Solutions Claire Riches dives into the FDA’s plans to use RWD to streamline the drug approval process
April 22, 2025 – An article in Therapeutic Innovation & Regulatory Science notes how Citeline’s Trialtrove database was used to conduct an analysis to estimate the IRA’s impact on the initiation of industry-sponsored Phase I-III trials in previously approved drugs
March 31, 2025 – Jake Mathon’s insights are shared in a PharmaVoice article on adeno-associated viruses (AAV)
March 11, 2025 – In an executive interview with The Clinical Trial Vanguard, Claire Riches, Vice President – Clinical Solutions, shares Citeline’s strategic vision for bridging clinical trials and real-world healthcare
March 6, 2025 – In an article he wrote for MedCity News, Luca Parisi, Director of Clinical Analytics and Data Science, sees a promising future for the use of AI in drug development
March 5, 2025 – A BioXconomy  article on the AbbVie/Gubra deal for obesity drugs features Tim Blackstock’s comments
Feb. 27, 2025 – Men’s Health, one of the UK’s largest consumer health magazines, features Tim Blackstock’s commentary on the race to develop an oral weight loss drug
Feb. 26, 2025 – A PharmaVoice article on the development of therapeutic cancer vaccines features commentary from James Drew, Director of Content Strategy – Technology
Feb. 20, 2025 – An academic paper by Citeline subject matter experts and our quarterly ASGCT report were cited in an article on News Medical
Feb. 16, 2025 – Citeline’s US vs. China R&D comparison data was cited in an article in The Economist (subscription required)
Feb. 10, 2025 – In an article for PharmaLive, Healthcare Analyst Emma Wille provides an overview of the depression treatment landscape from novel psychedelic therapies to traditional medicines
Jan. 6, 2025 – Sara LaFever, executive director, product services, offers her predictions in PharmaVoice for promising drug approvals in 2025

Dec. 12, 2024 – Healthcare analyst Emma Wille is quoted in an HCPLive article on the mental health crisis
Dec. 10, 2024 – Senior analyst David Dahan offers commentary on GSK’s antibody-drug conjugate Blenrep in PharmaVoice
Dec. 5, 2024 – An article in The Economist on the weight-loss drug pipeline includes data provided by Citeline (subscription required)
Dec. 1, 2024 – Dr. Annie Siu and Saakshi Gupta share their insights on 2025 trends for the APAC region in BioSpectrum Asia
Nov. 20, 2024 – An article in PharmaVoice around the viability of the Biosecure Act quotes Pink Sheet Editor in Chief Nielsen Hobbs
Oct. 16, 2024 – In an article on AstraZeneca’s Farxiga blockbuster drug, PharmaVoice references Citeline’s “Billion Dollar Blueprint: The Journey to Blockbuster Status” report
Oct. 5, 2024 – Citeline data are referenced in a Financial Times article on GLP-1 weight-loss drugs (subscription required)
Sept. 27, 2024 – In MedCity News, Summer Colling concurs with the prevailing belief that KarXT will not be a first-line treatment for schizophrenia
Sept. 27, 2024 – Senior analyst Summer Colling provides commentary on the schizophrenia treatment KarXT in C&EN
Sept. 16, 2024 – Nielsen Hobbs shared his predictions on the future of the BIOSECURE Act with PharmaVoice
Sept. 12, 2024 – Commentary from analyst Nielsen Hobbs on the BIOSECURE Act is featured in STAT’s DC Diagnosis Newsletter
Aug. 30, 2024 – Pharmacy Times included commentary from Pam Spicer, therapy area director, on the current state of Alzheimer’s drugs coming to market and their potential impact on physicians and patients
Aug. 27, 2024 – Data from Trialtrove was included in a Financial Times (MUU: 36,500,000) article on the current landscape for oncology treatment (registration required)
Aug. 23, 2024 – Therapy Area Director Pam Spicer is featured in a Pharmacy Times “Pharmacy Focus” podcast on the current pipeline of Alzheimer’s drugs
Aug. 4, 2024 – Brian Yang’s commentary was included in an in-depth The Wire China article discussing Novo Nordisk’s Ozempic, the GLP-1 market in China, and the wider Chinese biopharma industry (subscription required)
June 21, 2024 – A MedCity News article cites both principal analyst Amanda Micklus and Citeline data regarding precedents for the Sarepta gene therapy approval
June 13, 2024 – Endpoints News cited Citeline figures on Lu-177 trials in an article warning of a shortage of lutetium (registration required)
June 5, 2024 – In its ASCO coverage, PharmaLive and its Daily Advantage newsletter included commentary from several Citeline analysts
June 3, 2024 – Claire Riches is interviewed regarding her role as a woman leader in pharma on The Pharma Recruiter podcast
May 30, 2024 – Swiss national publication Swissinfo, part of the Swiss Broadcasting Corporation, included a graphic with Citeline data on AI dealmaking
May 17, 2024 – Life Science Sweden ran a dedicated analysis of the Annual Pharma R&D Review and its insights, including an interview with Ian Lloyd
May 8, 2024 – In an article in The Times, Dan Chancellor provides context for AstraZeneca’s withdrawal of its COVID-19 vaccine. (subscription required)
May 2, 2024 – In an article on Q1 earnings, MM&M featured commentary on Moderna from analyst Flora Mackay
Apr. 25, 2024 – Analyst Dana Gheorge is quoted in an Investor’s Business Daily article on radiopharmaceuticals
Apr. 24, 2024 – As part of our quarterly earnings analyses, MM+M featured Joseph Jacob’s commentary around Roche’s Q1 earnings
Mar. 30, 2024 – The Economist featured Citeline data on AI-related pharmaceutical expenditures in its Technology Quarterly on healthcare and AI
Mar. 7, 2024 – David Ridley offers his insights in an article in The Economist on nootropics
Mar. 7, 2024 – New Scientist included a comment from Dan Chancellor on Novo Nordisk’s Phase I trial readout for amycretin
Mar. 6, 2024 – Analyst Summer Colling is extensively quoted in PharmaVoice (19.7K+ UVM) around schizophrenia treatment innovation
Feb. 26, 2024 – Analyst Khang Koang is quoted in PharmaVoice in an article on the skyrocketing sales of diabetes and weight loss GLP-1 receptors
Feb. 21, 2024 – A PharmaVoice article on biotechs to watch in 2024 uses data and quotes from Biomedtracker’s forecasting report
Feb. 15, 2024 – PharmaVoice quoted Therapy Area Director Pam Spicer in an article on Biogen’s Q4 earnings
Feb. 15, 2024 – City A.M. included Dan Chancellor’s commentary on GSK’s acquisition of Aiolos Bio
Feb. 13, 2024 – Khang Hoang, Citeline cardiovascular and metabolic and infectious diseases analyst, is quoted in Drug Discovery & Development on additional indications for GLP-1s
Feb. 13, 2024 – Investor’s Business Daily included comments from analyst Pamela Spicer on Biogen’s Q4 earnings, focusing on the slow launch of Leqembi
Feb. 8, 2024 – UK business national This Is Money included healthcare analyst Summer Colling’s commentary on AstraZeneca earnings in its live business blog
Jan. 22, 2024 – In a PharmaVoice article on a universal COVID vaccine, senior analyst Natasha Boliter shares her insights on the logistical advantage of a combination COVID, RSV, and flu vaccine
Jan. 22, 2024 – PharmaVoice included commentary from Jake Mathon and Sheila Omondi around challenge trials, as well as supporting data from Citeline
Jan. 5, 2024 – A PharmaVoice article on the state of infectious disease featured comments from senior analysts Natasha Boliter and Charlotte Holmes